Market Cap 46.72M
Revenue (ttm) 0.00
Net Income (ttm) -71.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 323,700
Avg Vol 759,766
Day's Range N/A - N/A
Shares Out 15.02M
Stochastic %K 96%
Beta 2.70
Analysts Strong Sell
Price Target $14.29

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic sp...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 549 1400
Address:
2200 Bridge Pkwy, Suite 102, Redwood City, United States
Messerschmittbf109
Messerschmittbf109 Aug. 15 at 3:13 PM
$KIDZ $JSPR poor people …poor sh … t … s
0 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 2:21 PM
UBS has adjusted their stance on Jasper Therapeutics ( $JSPR ), setting the rating to Buy with a target price of 29 → 25.
0 · Reply
Drosendale88
Drosendale88 Aug. 15 at 2:19 PM
$JSPR from the report: “As of June 30, 2025, the Company had an accumulated deficit of $288.8 million. The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support the Company’s cost structure.”
0 · Reply
Drosendale88
Drosendale88 Aug. 15 at 2:13 PM
$JSPR I thought this was a fallen angel in January when it dove from 20 to 7 and while I still think it’s undervalued.. It has $39.5M in cash and eq but $27M in expenses last quarter alone, not sure they’ll make it to the end of the year without tapping into their shelf
1 · Reply
Messerschmittbf109
Messerschmittbf109 Aug. 15 at 5:49 AM
$JSPR wen the level of competence is low This is the result..from 22 to 3$ in 7 months
0 · Reply
Bullshyte
Bullshyte Aug. 15 at 5:00 AM
$JSPR take no chance. Make no money. This will eventually make you very rich if you buy here and stay patient. Mark it.
1 · Reply
Messerschmittbf109
Messerschmittbf109 Aug. 14 at 6:10 PM
$JSPR crazy … friends of friends of friends 20$ 😂
1 · Reply
Dahoom93
Dahoom93 Aug. 14 at 10:06 AM
1 · Reply
DCRMIA
DCRMIA Aug. 14 at 9:39 AM
$JSPR is about to skyrocket. Fasten your seatbelt🚀🚀🚀
2 · Reply
Lamatozore
Lamatozore Aug. 14 at 8:56 AM
$JSPR back 3$ today
0 · Reply
Latest News on JSPR
Jasper Therapeutics to Present at Upcoming Investor Conferences

May 14, 2025, 4:30 PM EDT - 3 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences


Messerschmittbf109
Messerschmittbf109 Aug. 15 at 3:13 PM
$KIDZ $JSPR poor people …poor sh … t … s
0 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 2:21 PM
UBS has adjusted their stance on Jasper Therapeutics ( $JSPR ), setting the rating to Buy with a target price of 29 → 25.
0 · Reply
Drosendale88
Drosendale88 Aug. 15 at 2:19 PM
$JSPR from the report: “As of June 30, 2025, the Company had an accumulated deficit of $288.8 million. The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support the Company’s cost structure.”
0 · Reply
Drosendale88
Drosendale88 Aug. 15 at 2:13 PM
$JSPR I thought this was a fallen angel in January when it dove from 20 to 7 and while I still think it’s undervalued.. It has $39.5M in cash and eq but $27M in expenses last quarter alone, not sure they’ll make it to the end of the year without tapping into their shelf
1 · Reply
Messerschmittbf109
Messerschmittbf109 Aug. 15 at 5:49 AM
$JSPR wen the level of competence is low This is the result..from 22 to 3$ in 7 months
0 · Reply
Bullshyte
Bullshyte Aug. 15 at 5:00 AM
$JSPR take no chance. Make no money. This will eventually make you very rich if you buy here and stay patient. Mark it.
1 · Reply
Messerschmittbf109
Messerschmittbf109 Aug. 14 at 6:10 PM
$JSPR crazy … friends of friends of friends 20$ 😂
1 · Reply
Dahoom93
Dahoom93 Aug. 14 at 10:06 AM
1 · Reply
DCRMIA
DCRMIA Aug. 14 at 9:39 AM
$JSPR is about to skyrocket. Fasten your seatbelt🚀🚀🚀
2 · Reply
Lamatozore
Lamatozore Aug. 14 at 8:56 AM
$JSPR back 3$ today
0 · Reply
d_risk
d_risk Aug. 14 at 3:13 AM
$JSPR - Jasper Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors JSPR flags new risks from its corporate reorg, tax law changes, and resource allocation choices, while expanding on clinical trial delays, patient enrollment, regulatory and economic pressures, and dilution from new equity plans. #Biotechnology #EquityDilution #EconomicPressure #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/JSPR/10-Q/2025-08-13
0 · Reply
BioTechChap
BioTechChap Aug. 13 at 10:19 PM
$JSPR The worst thing of the delay in the ‘product lot variability’ assessment is that probably no tute is willing to take the risk and invest heavily in this company. Tricky Catch-22 situation they have ended up with.
1 · Reply
Stmkr
Stmkr Aug. 13 at 9:02 PM
$JSPR Still investigating the bad lot? come on...
0 · Reply
BioTechChap
BioTechChap Aug. 13 at 8:10 PM
$JSPR Nothing on financial injection. Must be something cooking. Ridiculous that batch investigation runs into eoy.
4 · Reply
DarkOrb
DarkOrb Aug. 13 at 8:09 PM
$JSPR These weasels just dumped their 10Q after the close... Still investigating their broken trial. No quarterly call scheduled. https://ir.jaspertherapeutics.com/news-releases/news-release-details/jasper-therapeutics-reports-second-quarter-2025-financial
0 · Reply
BioTechChap
BioTechChap Aug. 13 at 6:00 PM
$JSPR Wouldn’t be surprised to see a PIPE transaction with substantial dilution, but hey the lights must stay on and the show must go on
1 · Reply
BioTechChap
BioTechChap Aug. 13 at 5:53 PM
$JSPR Waiting for some updates on IMP batch and financing. Took some XFOR gains to average down on this one. Respected institutional healthcare investors know how to scout an undervalued, high potential asset. GL folks
0 · Reply
wilberth92
wilberth92 Aug. 13 at 5:31 PM
0 · Reply
yung_priest_
yung_priest_ Aug. 13 at 3:23 AM
$JSPR Take Me Back To $7
0 · Reply
Dahoom93
Dahoom93 Aug. 13 at 12:40 AM
0 · Reply
Lamatozore
Lamatozore Aug. 12 at 8:05 PM
$JSPR lets go hit 3$ tomorrow
0 · Reply
msoi
msoi Aug. 12 at 2:15 PM
$JSPR those which followed me made at least 12% gains here
0 · Reply